Searching…
Apr 20, 2022 · Purpose: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide signific...
Feb 8, 2023 · Cancer and Leukemia Group B (CALGB) 140503 was a multicenter, international, randomized, noninferiority, phase 3 trial involving patients with NSCLC clinically staged as T1aN0.
Jun 6, 2016 · 当地时间 6 月 5 日，美国加利福尼亚大学 Alan P. Venook 教授就「转移性结直肠癌原发肿瘤位置对总生存（OS）和无进展生存（PFS）的影响：来自 CALGB/SWOG 80405 研究的分析结果」进行专题报告。
The CALGB 40603 trial protocol was approved by the central institutional reviewboard of the National CancerInstitute,as well as institutional review boards at the participating sites.
2月9日，NEJM杂志在线公布了一项III期、国际多中心、非劣效性随机CALGB 140503研究，旨在评估亚肺叶切除术（楔形切除术或肺段切除术）vs肺叶切除术在IA期NSCLC患者（肿瘤大小≤ 2 cm）的有效性。
Jan 25, 2025 · The results from the CALGB (Alliance) / SWOG 80702 study mark an unprecedented moment in personalized medicine for patients with colorectal cancer,” said Alexey Aleshin, M.D., corporate chief medical of...
Jul 30, 2025 · From 2008 to 2012, the US Intergroup conducted Cancer and Leukemia Group B (CALGB) 10403 (C10403), a prospective phase 2 clinical trial investigating whether a pediatric regimen for acute lymphoblastic ...
Jan 19, 2022 · CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly inc...
501O CALGB/SWOG 80405: PHASE III TRIALOF IRINOTECAN/5-FU/ LEUCOVORIN (FOLFIRI) OROXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED ...
Dec 10, 2020 · In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within...
